Start with the question, not the panel
Tell us what you are trying to find out, what samples you have, and what decision the data has to support. We will tell you how broad you need to go, what will realistically be detectable, and how to design the study so the results can be acted on.
That reply comes within one working day.
WHY IT MATTERS
Discovery lives or dies on depth, sensitivity and confidence
Early discovery has to do three things well.
Depth
Measure broadly enough to find biology you did not already know to look for. A narrow panel can only confirm or deny what you already suspected.
Sensitivity
Detect low-abundance signals before they become obvious. The markers that move first are usually the ones sitting closest to the detection floor.
Confidence
Generate data reproducible enough to support the next experimental decision. A discovery finding you cannot rely on is worse than no finding, because it costs you a validation study to disprove.
Broad profiling only creates value when the data is strong enough to tell you what to pursue next.
WHat we measure
Go broad enough to discover. Focus when the data tells you where.
Broad protein discovery
Multi-omic discovery
Defined pathways and proprietary biology
Interpretation and prioritisation
Applications
WHY discovery & early research
From broad discovery to focused validation
Discovery
Start broad enough to identify meaningful biological signals, before you know which ones matter.
Prioritisation
Use bioinformatics and biological context to decide which findings are worth carrying forward, and which are noise that would cost you a validation study.
Focused validation
Move selected biomarkers onto Simoa or MSD for preclinical and translational work, with absolute quantitation and a validation history behind the method.
Because NULISA, Simoa, MSD, sequencing and bioinformatics all sit in the same laboratory and the same scientific team, that transition happens without losing context, time or sample material.
The team validating a finding is the team that generated it, and they know which markers sat near the detection floor and where the batch boundaries fell.
Moving platform between stages is expected and correct; moving supplier as well adds variation you then have to account for in every downstream comparison.
The practical detail
Turnaround
Two weeks from sample receipt, confirmed at quote
Quote
Sample confirmation
Discovery breadth
Sample volume
Matrices
Cohort size
Analysis included
Quality framework
The research journey
Discovery is the beginning, not the destination.
01
Discovery & Early Research
Current stage
Broad profiling, target identification, hypothesis generation.
02
Preclinical Development
Target engagement, pharmacodynamic biomarkers, toxicology endpoints, and translational bridging from in vitro through to first-in-human.
Explore
03
Translational & Clinical Research
Validated biomarker workflows for clinical trial endpoints, regulatory-grade bioanalysis, patient stratification, and longitudinal monitoring.
Explore